Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Requirement for therapeutic inhibition of sickle haemoglobin gelation.

Literature DB >> 692700

Requirement for therapeutic inhibition of sickle haemoglobin gelation.

H R Sunshine, J Hofrichter, W A Eaton.

Abstract

Mesh：

Substances：

Year: 1978 PMID： 692700 DOI： 10.1038/275238a0

Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962

Keyword Cloud
Cited

× No keyword cloud information.

40 in total

1. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo.

Authors: C A Head; C Brugnara; R Martinez-Ruiz; R M Kacmarek; K R Bridges; D Kuter; K D Bloch; W M Zapol
Journal: J Clin Invest Date: 1997-09-01 Impact factor: 14.808

2. An embryonic/fetal beta-type globin gene repressor contains a nuclear receptor TR2/TR4 heterodimer.

Authors: Osamu Tanabe; Fumiki Katsuoka; Andrew D Campbell; Weimin Song; Masayuki Yamamoto; Keiji Tanimoto; James Douglas Engel
Journal: EMBO J Date: 2002-07-01 Impact factor: 11.598

3. Understanding the shape of sickled red cells.

Authors: Garrott W Christoph; James Hofrichter; William A Eaton
Journal: Biophys J Date: 2004-11-12 Impact factor: 4.033

Review 4. Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease.

Authors: Megan D Hoban; Stuart H Orkin; Daniel E Bauer
Journal: Blood Date: 2016-01-12 Impact factor: 22.113

5. RNA Trans-Splicing Targeting Endogenous β-Globin Pre-Messenger RNA in Human Erythroid Cells.

Authors: Naoya Uchida; Kareem N Washington; Brian Mozer; Charlotte Platner; Josiah Ballantine; Luke P Skala; Lydia Raines; Anna Shvygin; Matthew M Hsieh; Lloyd G Mitchell; John F Tisdale
Journal: Hum Gene Ther Methods Date: 2017-02-14 Impact factor: 2.396

10. The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects.

Authors: P E Rolan; J E Parker; S J Gray; B C Weatherley; J Ingram; W Leavens; R Wootton; J Posner
Journal: Br J Clin Pharmacol Date: 1993-04 Impact factor: 4.335

Requirement for therapeutic inhibition of sickle haemoglobin gelation.

1. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo.

2. An embryonic/fetal beta-type globin gene repressor contains a nuclear receptor TR2/TR4 heterodimer.

3. Understanding the shape of sickled red cells.

Review 4. Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease.

5. RNA Trans-Splicing Targeting Endogenous β-Globin Pre-Messenger RNA in Human Erythroid Cells.

Review 6. 2015 Clinical trials update in sickle cell anemia.

Review 7. Treating sickle cell disease by targeting HbS polymerization.

Review 8. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.

9. Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.

10. The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects.